TC BioPharm (Holdings) plc American Depositary Receipt
TCBPY
TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapy products derived from its proprietary allogeneic gamma delta T cell platform. Founded in 2013 and headquartered in Motherwell, United Kingdom, the company focuses on advancing cell-based therapies for serious medical conditions. Its product pipeline includes OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy currently in phase 2/3 clinical trials targeting acute myeloid leukemia, and ImmuniStim, an unmodified cell therapy designed to treat viral infections and various cancers. TC BioPharm emphasizes the development of safer, cost-effective CAR-T cell therapies with the potential to address multiple cancer types and improve patient health outcomes. Operating within the biotechnology sector, TC BioPharm leverages its integrated preclinical to clinical development model to innovate in cancer and infectious disease treatment, contributing to advancements in cell therapy and immunotherapy research.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£12M
▼ -105.8% YoY
Op. Margin
–
ROIC
-224.26%
▲ +71.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£13M
▼ -17.7% YoY
Op. Cash Flow (TTM)
-£10M
▼ -191.6% YoY
Net Debt
£284K
Cash & Equiv.
£1M
Continue Research
Peers
Biotechnology · Pick stocks to compare with TCBPY
TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY) in three numbers
Questions about TC BioPharm (Holdings) plc American Depositary Receipt
Is TC BioPharm (Holdings) plc American Depositary Receipt a high-quality business?
TC BioPharm (Holdings) plc American Depositary Receipt scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at 794.7%. The Quality tab shows every check against its target.
Does TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY) pay a dividend?
No. TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 10 Jul 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing TCBPY
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.